ArticleBreast cancer research and treatment2026
Impact of axillary surgery on survival in de novo metastatic breast cancer with primary tumor resection.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe role of axillary surgery in patients with de novo metastatic breast cancer (dnMBC) undergoing primary site surgery is unclear. We evaluated patterns of axillary management and associations with overall survival (OS) in this population.
methodsWe used the National Cancer Database (2012-2020) to identify patients with dnMBC. Patients were grouped by receipt of breast surgery and axillary surgery (none, sentinel lymph node biopsy [SLNB] or axillary lymph node dissection [ALND]). Multivariable Cox proportional hazards models assessed factors associated with axillary surgery and OS.
resultsAmong 39,946 eligible patients, 7,808 (19.5%) underwent surgery of the primary site, of whom 79.8% underwent axillary surgery (79.5% ALND, 20.4% SLNB). Compared with no axillary surgery, those who underwent axillary surgery had more favorable clinicodemographic characteristics (younger, fewer comorbidities, lower T stage, bone-only metastases). In patients with clinically node-negative disease, 41.6% had pathologically negative nodes, with higher rates among those with HR+/HER- disease and those who did not have systemic therapy prior to surgery. On multivariable analysis, axillary surgery was independently associated with improved OS (HR 0.70; 95% CI 0.63-0.78; p<0.001).
conclusionAmong patients with dnMBC undergoing primary site surgery, axillary surgery was associated with improved survival in this retrospective analysis, though the effect is likely influenced by selection bias. Until prospective data define which subgroups may benefit, axillary surgery should be considered selectively, with SLNB preferred over ALND for patients without palpable adenopathy to minimize morbidity. Multidisciplinary evaluation remains essential to tailor surgical decisions that balance survival, function, and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.